https://orcid.org/0000-0002-9598-0309
![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
ABSTRACT
Periprocedural management of the anticoagulated patient can be as easy as continuing warfarin for a low bleeding risk procedure, holding a direct oral anticoagulant for 1 day prior and resuming 1 day later or as complex as emergent reversal with prothrombin complex concentrate, idarucizumab, or andexanet alfa. Patient-specific factors for thromboembolic risk and procedural bleeding risk determine timing of anticoagulation hold prior to and resumption after invasive procedures. Clinical trials and management studies in recent years have helped inform our approach to these patients, but much of the guidance is still based on expert consensus.
Conflict of interest
In accordance with Taylor & Francis policy and my ethical obligation as a researcher, I am reporting that Scott Kaatz has received research funding to his institution from Janssen and BMS and has served as a consultant for Janssen, BMS, Pfizer, Portola and Roche, companies that may be affected by the research reported in the enclosed paper. I have disclosed those interests fully to Taylor & Francis, and I have in place an approved plan for managing any potential conflicts arising from that involvement.
A reviewer on this manuscript has disclosed that they receive honoraria for ad-boards or Speakers Bureau from Aspen, Celgene, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Pfizer. The other peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.
Declaration of interest
The contents of the paper and the opinions expressed within are those of the authors, and it was the decision of the authors to submit the manuscript for publication.